These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34052583)

  • 1. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
    Adel RM; Lotfy RA; Darwish AS; Amer AS
    J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
    Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
    Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
    Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
    Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox and vitamin D
    Ghaith MM; El-Boshy M; Almasmoum H; Abdelghany AH; Azzeh FS; Almaimani RA; Idris S; Ahmad J; Mahbub AA; BaSalamah MA; Elzubeir ME; Refaat B
    J Trace Elem Med Biol; 2022 Dec; 74():127085. PubMed ID: 36179462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
    Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
    Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ellagic acid isolated from Clerodendrum viscosum leaves ameliorates iron-overload induced hepatotoxicity in Swiss albino mice through inhibition of oxidative stress and the apoptotic pathway.
    Shendge AK; Basu T; Panja S; Chaudhuri D; Mandal N
    Biomed Pharmacother; 2018 Oct; 106():454-465. PubMed ID: 29990833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
    Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
    Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
    Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H; Qin Y; Chen G; Zhao Y
    Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biogenic Silver and Zero-Valent Iron Nanoparticles by Feijoa: Biosynthesis, Characterization, Cytotoxic, Antibacterial and Antioxidant Activities.
    Hashemi Z; Ebrahimzadeh MA; Biparva P; Mortazavi-Derazkola S; Goli HR; Sadeghian F; Kardan M; Rafiei A
    Anticancer Agents Med Chem; 2020; 20(14):1673-1687. PubMed ID: 32560617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R; Ahmed J; Krishnan P; Jankharia B
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
    Shen JC; Zhang YC; Zhao MF
    Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
    Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic aspects of iron(III)-chelation therapy with deferasirox (DFX) revealed by the solvolytic dissociation rate of the Fe(III)-DFX complex estimated with capillary electrophoretic reactor.
    Suzuki R; Iki N
    J Inorg Biochem; 2023 Apr; 241():112131. PubMed ID: 36706491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
    Salehi S; Saljooghi ASh; Shiri A
    Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.
    Goswami D; Vitorino HA; Alta RY; Silvestre DM; Nomura CS; Machini MT; Espósito BP
    Biometals; 2015 Oct; 28(5):869-77. PubMed ID: 26164834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina.
    Sakamoto K; Suzuki T; Takahashi K; Koguchi T; Hirayama T; Mori A; Nakahara T; Nagasawa H; Ishii K
    Exp Eye Res; 2018 Jun; 171():30-36. PubMed ID: 29530811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models.
    Imai T; Tsuji S; Matsubara H; Ohba T; Sugiyama T; Nakamura S; Hara H; Shimazawa M
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jan; 394(1):73-84. PubMed ID: 32808069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.